Can-Fite Biopharma Stock Forecast
NYSE: CANFHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 2.10 +5.00%
CANF analyst consensus
Consensus (1 analysts)
strong_buy
Avg. price target
$8.00+300.00%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 1 Wall Street analyst covering Can-Fite Biopharma (2026-10-09), 1 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $8.00, with a high estimate of $8.00 and a low estimate of $8.00. The average target implies upside of 300.0% from the current price of $2.00.
The spread between the highest and lowest targets is 0.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CANF.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 1 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $8.00 | +300.00% |
| Average target | $8.00 | +300.00% |
| High target | $8.00 | +300.00% |